Global Testosterone Replacement Therapy (TRT) Market to Exceed $5.0 Billion by 2017, According to New Report by Global Industry Analysts, Inc.

San Jose, CA (PRWEB) April 26, 2011

Testosterone Replacement Therapy (TRT) represents a nascent and evolving market. With a current treatment penetration rate of less than 10% in the US, the most advanced TRT market, and less than 5% in Europe and 1% in the developing countries, the TRT market holds immense future potential. Testosterone deficiency or hypogonadism is a widely prevalent condition, with the estimated incidence rate varying from 10% to 40% in the population above 45 years of age. Testosterone replacement is also underway for use in females, with new drugs such as LibiGel®, developed by BioSante and Luramist, developed by Acrux, in different phases of clinical trials for use in Hypoactive Sexual Desire Disorder (HSDD), a condition characterized by absence of sexual desire. Lured by the high potential in the market several pharmaceutical companies are developing new drugs and delivery systems for TRT. Innovative and improved delivery systems that overcome the issues with the existing solutions are expected to expand the market by bringing in hitherto untapped patient groups within the ambit of treatment.

Topical gels were first introduced in 2000 and currently represent the predominantly used therapy, as stated by the new market research report on Testosterone Replacement Therapy (TRT). Apart from Androgel and Testim, the two dominant gel brands in the market, other gels in the market include Tostran and the recently approved Axiron, while Bio-T-Gel, and other gels are currently at different stages of clinical trials. The United States dominates the global TRT market, with gels being the predominant segment. Though the use of injections has declined significantly in the US subsequent to the introduction of gels, but they retain significant share in the European market.

Global TRT market is highly consolidated, with the three top brands, Androgel, Testim and Androderm, accounting for a major share of the global value market. Apart from biotechnology companies and specialty pharmaceutical firms, the TRT market is also witnessing the foray of large multinational pharmaceutical companies such as Eli Lilly, Bayer Schering, GlaxoSmithKline Plc., and Abbott Laboratories. Other players in the TRT market include Acrux Limited, Auxilium Pharmaceuticals, Inc., Endo Pharmaceuticals, Inc., ProStrakan Group PLC, Slate Pharmaceuticals, Inc., and Watson Pharmaceuticals Inc.

The research report titled “Testosterone Replacement Therapy (TRT): A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, issues, drivers, company profiles, mergers, acquisitions and other strategic industry activities. The report provides market estimates and projections in US$ Million for Testosterone Replacement Therapy by three product segments: Gels, Patches, and Others (including injectables, oral, pellets, and buccals) for major geographic markets including the US, Canada, Europe, Asia-Pacific, Latin America and the Rest of World.

For more details about this comprehensive market research report, please visit –

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

E-mail: press(at)StrategyR(dot)com

Web Site:


Find More Testosterone Injections Press Releases